Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | SLC37A4 | O43826 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900081 | 1.00 | GALK1 (0.40) | GALK1OPRM1FAAHTRPV1SLC37A4 | |
| SCHEMBL13902236 | 0.86 | CCR5 (0.39) | OPRM1FAAHTRPV1SLC37A4CCR5 | |
| SCHEMBL13902230 | 0.78 | EPHX2 (0.41) | TRPV1SLC37A4CNR1EPHX2CNR2 | |
| SCHEMBL3901498 | 0.76 | OPRM1 (0.47) | OPRM1FAAHTRPV1CCR5 | |
| SCHEMBL3901500 | 0.76 | OPRM1 (0.47) | OPRM1FAAHTRPV1CCR5 | |
| SCHEMBL13562270 | 0.68 | TOP2A (0.44) | TRPV1EPHX2 | |
| SCHEMBL10482226 | 0.68 | CYSLTR2 (0.50) | FAAHTRPV1CNR1EPHX2CNR2 | |
| SCHEMBL8500643 | 0.68 | CYSLTR2 (0.50) | FAAHTRPV1CNR1EPHX2CNR2 | |
| SCHEMBL8500639 | 0.68 | CYSLTR2 (0.50) | FAAHTRPV1CNR1EPHX2CNR2 | |
| SCHEMBL9857570 | 0.68 | CYSLTR2 (0.50) | FAAHTRPV1CNR1EPHX2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1882523-B | Novel phenol derivative, and anti-trypanosomiasis medicine with the phenol derivative as effective ingredient | ARIJI KK | 2010-11-17 | — | — | CN | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-1681280-B1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ARIGEN PHARMACEUTICALS INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1681280-B1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ARIGEN PHARMACEUTICALS INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| CN-1882523-A | Novel phenol derivative, and anti-trypanosomiasis medicine with the phenol derivative as effective ingredient | ARIJI KK (JP) | 2006-12-20 | — | — | CN | disclosed |
| EP-1681280-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | aRigen, Inc. (JP) | 2006-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | TYR, H1-3, H1-0 | GALK1 3126/4885OPRM1 2281/4885FAAH 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.